Bergman Simon, Mikami Dean J, Hazey Jeffrey W, Roland Jason C, Dettorre Rebecca, Melvin W Scott
Department of Surgery, Center for Minimally Invasive Surgery, The Ohio State University, Columbus, Ohio 43210, USA.
Surg Innov. 2008 Sep;15(3):166-70. doi: 10.1177/1553350608321588.
EsophyX is a novel endolumenal therapeutic option for the treatment of gastroesophageal reflux disease (GERD). The device is passed into the stomach, where it deploys a series of full-thickness fasteners to create a neogastroesophageal valve. The objective of this study was to demonstrate the safety and characterize the effectiveness of this approach in the initial North American experience. This is a retrospective study of consecutive patients with GERD who had undergone endolumenal fundoplication with the EsophyX device. At follow-up, proton pump inhibitor usage was elicited and 2 validated questionnaires were administered measuring GERD health-related quality of life (range 0-50) and symptom severity (range 0-72). In limited preliminary evaluation, the initial North American experience with endolumenal fundoplication using the EsophyX device is that it appears to be safe and provides moderate effectiveness in treating the symptoms of GERD. Further studies comparing this technique with conventional medical and surgical therapies are necessary.
EsophyX是一种用于治疗胃食管反流病（GERD）的新型腔内治疗方法。该设备被送入胃内，在那里它部署一系列全层紧固件以创建一个新的胃食管瓣膜。本研究的目的是在北美首次应用中证明这种方法的安全性并描述其有效性。这是一项对连续接受EsophyX设备腔内胃底折叠术的GERD患者进行的回顾性研究。在随访时，了解质子泵抑制剂的使用情况，并发放两份经过验证的问卷，测量与GERD健康相关的生活质量（范围0 - 50）和症状严重程度（范围0 - 72）。在有限的初步评估中，北美首次使用EsophyX设备进行腔内胃底折叠术的经验表明，它似乎是安全的，并且在治疗GERD症状方面具有中等疗效。有必要进行进一步的研究，将这种技术与传统的药物和手术疗法进行比较。
